The present invention discloses a marker of intestinal metagenomic characterization for acarbose efficacy screening in patients with type 2 diabetes, wherein the intestinal microorganism methenomenal feature is a bacteroid enterotypic. It has been found that the therapeutic response to acarbose, a diabetic lowering drug, in patients with type 2 diabetes mellitus having different intestinal microflora groups is remarkable by using the concept of enterotypes for the first time in the present invention. Therefore, before using the drug, the patient can be distinguished according to the enterotypes, the group with the optimal effect can be selected, and the type 2 diabetic patient can judge whether it is appropriate to proceed with diabetic treatment using Akaboz can do. In addition, the general classification of the enterotypes is to proceed with sequencing or PCR amplification of the DNA of the parasites in the stool; In the baseline, the bile acid component, particularly the secondary bile acid, can be used to distinguish the enterotypes; The enterotypes can be distinguished by blood markers and can be used as markers for diagnosis.
展开▼
